Randomized controlled study of propranolol for prevention of recurrent esophageal varices bleeding in patients with cirrhosis.
A randomized controlled trial of propranolol was conducted in 36 adult cirrhotic patients after active esophageal variceal hemorrhage had been controlled. Seventy-eight percent of the 18 patients on propranolol and 72% of the patients on a placebo were of Pugh's class A. Of the patients treated with propranolol, 94%, 87%, 68% and 57% were free from rebleeding 6, 12, 18 and 24 months after entry, respectively. The corresponding figures in control patients were 81%, 59%, 30% and 15%, respectively. The percentages of patients free from rebleeding were significantly higher in the propranolol group than in the control group (P less than 0.05). No significant adverse effect was observed during the study, except for a patient who developed hepatic decompensation 14 months after propranolol therapy. It was concluded that propranolol was a safe and effective drug for the prevention of variceal rebleeding in patients with good liver functional reserve.
Sheen
I S
IS
Liver Unit, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
Chen
T Y
TY
Liaw
Y F
YF
D000328:Adult; D002986:Clinical Trials as Topic; D004932:Esophageal and Gastric Varices / Q000188:drug therapy*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use*; D011897:Random Allocation
D010919:Placebos; D011433:Propranolol